Cytomegalovirus endotheliitis after fluocinolone acetonide (Retisert) implant in a patient with Behcet uveitis
Purpose: To report a case of cytomegalovirus (CMV) endotheliitis after insertion of an
intravitreal fluocinolone acetonide (Retisert) implant. Design: Interventional case report.
Methods: Retrospective chart review. Results: A 40-year-old man received a Retisert implant
in the left eye for recurrent Behçet uveitis. Although inflammation became quiescent within a
month, corneal edema developed 4 months after insertion. Polymerase chain reaction
analysis for aqueous humor detected 3.9× 104 copies/mL of CMV DNA. After treatment with …
intravitreal fluocinolone acetonide (Retisert) implant. Design: Interventional case report.
Methods: Retrospective chart review. Results: A 40-year-old man received a Retisert implant
in the left eye for recurrent Behçet uveitis. Although inflammation became quiescent within a
month, corneal edema developed 4 months after insertion. Polymerase chain reaction
analysis for aqueous humor detected 3.9× 104 copies/mL of CMV DNA. After treatment with …
Purpose: To report a case of cytomegalovirus (CMV) endotheliitis after insertion of an intravitreal fluocinolone acetonide (Retisert) implant. Design: Interventional case report.
Methods: Retrospective chart review.
Results: A 40-year-old man received a Retisert implant in the left eye for recurrent Behçet uveitis. Although inflammation became quiescent within a month, corneal edema developed 4 months after insertion. Polymerase chain reaction analysis for aqueous humor detected 3.9 × 104 copies/mL of CMV DNA. After treatment with oral valganciclovir, CMV DNA nearly disappeared but visual outcome was poor due to corneal decompensation resulting from severe endothelial cell loss.
Conclusions: After Retisert implant, clinicians should be attentive to the potential risk of CMV endotheliitis.
Taylor & Francis Online以上显示的是最相近的搜索结果。 查看全部搜索结果